Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+ HER2- Breast Cancer”

614 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 614 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT06680596
What this trial is testing

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Who this might be right for
Breast Cancer MetastaticBreast Cancer Stage IV
UNICANCER 80
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661
What this trial is testing

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 109
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Not applicableActive Not RecruitingNCT04854005
What this trial is testing

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Looking for participantsNCT07581834
What this trial is testing

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Who this might be right for
Breast DiseasesBreast NeoplasmsDalpiciclib+3 more
Fujian Cancer Hospital 2,000
Large-scale testing (Phase 3)Not Yet RecruitingNCT07784036
What this trial is testing

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Chengdu JOYO pharma Co., Ltd. 171
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Large-scale testing (Phase 3)Looking for participantsNCT06383767
What this trial is testing

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Qilu Pharmaceutical Co., Ltd. 378
Testing effectiveness (Phase 2)Looking for participantsNCT05867251
What this trial is testing

Study of AVZO-021 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more
Avenzo Therapeutics, Inc. 430
Testing effectiveness (Phase 2)UnknownNCT04088110
What this trial is testing

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Fuzhou General Hospital 77
Testing effectiveness (Phase 2)Looking for participantsNCT06914440
What this trial is testing

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Xijing Hospital 27
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Large-scale testing (Phase 3)UnknownNCT05439499
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 434
Large-scale testing (Phase 3)Looking for participantsNCT07019363
What this trial is testing

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Who this might be right for
Breast CancerAdjuvant Therapy
Fudan University 1,903
Testing effectiveness (Phase 2)Ended earlyNCT01528345
What this trial is testing

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 97
Testing effectiveness (Phase 2)UnknownNCT05025735
What this trial is testing

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-negative Breast Cancer
Saint Luke's Health System 25
Next Page